RE:RE:RE:H. C. Wainwright 22nd Annual Global Investment Conference Hey Eric, I agree that CEO compensation is way out of whack for a tiny revenue company with major clinical trials to come but I believe that salary was $500K, cash bonus was approx $300K
and the rest is equity based of shares/options for $11M. He does not deserve equity worth this much until he executes and a reasonable $2M equity compensation would reach $11M on performance. At least it's not cash but tremendously over paid for not having accomplished much. Don't know what Thomvest is thinking.
eric40 wrote: Cut Galbraith salary and they will save 1 million a month.
What a joke, Thomvest gave him a 12 millions $ a year salary gift for grabbing the company from existing shareholders
That's how it is when they control a company.
Shareholder of Liminal have the right to vote but their vote worth nothing since Thomvest has the majority of shares.
Hopefully, the FDA will give a YES to the BLA resubmission and this will give a boost to the shareprice.
We should know within 8 days, by september 23, since the FDA has 14 days to reply after the BLA resubmission.
GLTA